Striatal specificity of gene expression dysregulation in Huntington's disease.
about
The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice.Modeling Huntington's disease with induced pluripotent stem cellsPossible involvement of self-defense mechanisms in the preferential vulnerability of the striatum in Huntington's diseaseFunctional roles for the striatal-enriched transcription factor, Bcl11b, in the control of striatal gene expression and transcriptional dysregulation in Huntington's diseaseExpression analysis of novel striatal-enriched genes in Huntington disease.Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysisTranscriptional activation of REST by Sp1 in Huntington's disease modelsDifferential vulnerability of neurons in Huntington's disease: the role of cell type-specific features.Proteostasis in striatal cells and selective neurodegeneration in Huntington's disease.Mitochondrial loss, dysfunction and altered dynamics in Huntington's diseaseIn vivo cell-autonomous transcriptional abnormalities revealed in mice expressing mutant huntingtin in striatal but not cortical neurons.Genetic analysis of genes causing hypertension and stroke in spontaneously hypertensive rats: Gene expression profiles in the kidneys.Glycolipid and ganglioside metabolism imbalances in Huntington's disease.Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington's disease mice: implications for the ubiquitin-proteasomal and autophagy systems.Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease.Poly-glutamine expanded huntingtin dramatically alters the genome wide binding of HSF1.Striatal development involves a switch in gene expression networks, followed by a myelination event: implications for neuropsychiatric disease.DNA methylation in Huntington's disease: Implications for transgenerational effectsInhibition of DNA Methyltransferases Blocks Mutant Huntingtin-Induced NeurotoxicityDistinct conformations of in vitro and in vivo amyloids of huntingtin-exon1 show different cytotoxicity.Mutant huntingtin and mitochondrial dysfunction.Increased expression of Bim contributes to the potentiation of serum deprivation-induced apoptotic cell death in Huntington's disease knock-in striatal cell line.Forkhead box protein p1 is a transcriptional repressor of immune signaling in the CNS: implications for transcriptional dysregulation in Huntington disease.High resolution time-course mapping of early transcriptomic, molecular and cellular phenotypes in Huntington's disease CAG knock-in mice across multiple genetic backgrounds.Aging causes distinct characteristics of polyglutamine amyloids in vivo.Neurocognitive disorders: cluster 1 of the proposed meta-structure for DSM-V and ICD-11.Targeting Gpr52 lowers mutant HTT levels and rescues Huntington's disease-associated phenotypes.
P2860
Q24656405-BB7EC8F7-CABE-4C67-9FF2-CFFCF0088D21Q27004209-585F42A9-668B-4E2A-97E7-25BC7B4EF9ADQ27011417-27D22B01-BC0E-45FB-9E6A-E81630A2BB3EQ28507781-C247ADFB-D048-4763-BCEF-971703C0E0FFQ30476999-F40D1821-E343-44A2-BC30-F526283B6A58Q33755822-EEBC6914-FC73-4D83-8E09-DC8AEEAE0A87Q33778522-3AC39E39-E662-456B-97FE-E26BED83A743Q33931283-B61CAF42-9016-4D35-99E0-34E62C00A625Q34014433-64E95424-2DF1-4C89-AD0F-0FC373EEE02FQ34163054-7A42E2B6-A67C-4BB1-AD9A-4E7F950FA172Q34597796-7A40784C-18D0-4CDD-8659-7F5278239D57Q35944692-DD6C9349-5EDF-42CC-81A3-60DFA751F484Q36151607-7490E46D-294D-41BF-80BF-AF1A733076CCQ36435854-C7843E9C-04DA-4D2C-908E-E6E07883A96FQ36482299-76BA0FCF-AE83-40F3-B9FA-8A5667FDDF1DQ36509945-FA7243C9-85D2-4F01-81D5-16A93F315A7DQ36626038-9768072B-249D-4749-BCDA-2F2E09F8D1A9Q36892975-C26DD2A6-DBAD-42CA-A892-6CA6958C0387Q37169118-EA182432-D6AA-4E7E-A27B-90D802D67388Q37209664-63EE9346-08E1-4FFD-953E-BB4422AFAD29Q37308357-022FF102-D24E-4C61-B152-06929B006620Q39952286-E82EBB6B-F756-4A58-9F5A-EEAD93C8F28FQ41873152-5B7E739A-3637-4C29-A306-F159D689D628Q45301191-B84111D0-02A8-4B76-B994-88C3602CED68Q45302330-FAA3E9AD-6AE8-4BB9-B44D-0B85F0E7C449Q48445053-667A8779-6674-4126-875C-6BFFA8F7396DQ52613225-FABF65C0-7A53-41EC-86EF-6D01F7137B7D
P2860
Striatal specificity of gene expression dysregulation in Huntington's disease.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Striatal specificity of gene expression dysregulation in Huntington's disease.
@ast
Striatal specificity of gene expression dysregulation in Huntington's disease.
@en
type
label
Striatal specificity of gene expression dysregulation in Huntington's disease.
@ast
Striatal specificity of gene expression dysregulation in Huntington's disease.
@en
prefLabel
Striatal specificity of gene expression dysregulation in Huntington's disease.
@ast
Striatal specificity of gene expression dysregulation in Huntington's disease.
@en
P2860
P356
P1476
Striatal specificity of gene expression dysregulation in Huntington's disease.
@en
P2093
Elizabeth A Thomas
P2860
P304
P356
10.1002/JNR.21046
P577
2006-11-01T00:00:00Z